Research Reagents and Contract Services Based on Antibody-Generation Technology

「Revenue from this service increased significantly year on year, owing to a substantial increase in domestic sales of raw materials for in vitro diagnostic products, higher overseas sales of the flagship ELISA kits, and increased sales of the bovine spongiform encephalopathy testing kit (BSE kit), an in vitro diagnostic product for veterinary use.」

「Revenue from this service increased year on year, supported by the continued adoption of the Company’s flagship ELISA kits in clinical trials conducted by overseas CROs, increased domestic sales of antibodies used as raw materials for in vitro diagnostic products, and steady sales of contract services and other offerings.」

「Although sales of veterinary in vitro diagnostic bovine spongiform encephalopathy measurement kits (BSE kits) declined, revenue from this service increased substantially year on year due to factors including higher overseas sales of the core ELISA kits and substantial antibody sales for raw materials for in vitro diagnostic products. Sales of contract services also increased. As a result, revenue from this service increased 14.8% year on year to ¥415.178 million.」

「Revenue from this service increased substantially year on year both domestically and overseas. Overseas sales benefited from the continued adoption of the high-margin core products Angiotensinogen (AGT) ELISA and Gd-IgA1 ELISA in clinical trials by overseas CROs, a substantial increase in sales of raw materials for in vitro diagnostic products in Japan and overseas, and steady sales of contract services and other products.」

「Domestic sales of the antibodies and ELISA kits that are core products of this service remained broadly in line with the previous year, while overseas sales increased substantially. Angiotensinogen (AGT) ELISA and Gd-IgA1 ELISA were adopted for clinical trials by overseas CROs, and substantial antibody sales were recorded. Sales of contract services and raw materials for in vitro diagnostic products, including mycoplasma pneumonia, also increased. As a result, revenue from this service increased 15.5% year on year to ¥361.523 million.」

「Revenue from this service increased substantially year on year both domestically and overseas as sales of the core ELISA kits rose significantly, driven by a substantial increase in sales to overseas CROs and the success of the social media strategy.」

「Sales of the core ELISA kits in this service continued to perform steadily both domestically and overseas. Meanwhile, revenue from antibody products and veterinary in vitro diagnostic bovine spongiform encephalopathy measurement kits (BSE kits), which had been recognized in substantial amounts during the same accounting period of the previous year, is now expected to be recognized from the fourth-quarter consolidated accounting period of the current fiscal year onward.」

「Revenue from the core ELISA kits in this service increased substantially year on year both domestically and overseas. Domestic antibody sales and reagent-related contract services also increased year on year. Sales of veterinary in vitro diagnostic bovine spongiform encephalopathy measurement kits (BSE kits) were broadly in line with the previous year.」

「The Company expects the news that Eisai Co.,Ltd.’s LEQEMBI® (lecanemab) was approved by the U.S. FDA as a treatment for Alzheimer’s disease to drive demand for its Alzheimer’s-related products.」

「Sales volumes of the Company’s core ELISA kits and antibodies increased substantially as its information strategy using e-marketing, including social media, for overseas sales increased inquiries from researchers at major overseas CROs, pharmaceutical companies and universities. Revenue also increased substantially year on year due to the weaker yen.」

「During the cumulative third quarter under review, the Group’s revenue substantially exceeded the previous year. Although testing services for LipoSEARCH under the antibody-related business declined, overseas sales volumes of the Group’s core ELISA kits and antibodies increased substantially, and the Group recorded substantial sales of Alzheimer’s-related antibodies in Japan and overseas.」

「The Group’s revenue exceeded the previous year as overseas sales of its core ELISA kits and antibodies increased substantially due to the weaker yen and a significant increase in sales volume.」

「During the cumulative first quarter under review, the Group’s revenue substantially exceeded the previous year, despite concerns about a renewed spread of COVID-19, as the substantial increase in overseas sales of its core diagnostic reagent services more than offset the decline in testing services under the antibody-related business for the blood lipoprotein profiling service LipoSEARCH.」

「During the cumulative third quarter under review, the Group’s revenue showed signs of recovery in Japan and overseas as research and development activities at companies and universities began to recover, led by sales of core reagent-related ELISA kits and antibodies.」

「Research and development activities at companies and universities in Japan and overseas began to recover, and signs of recovery emerged, led by sales of core reagent-related EIA measurement kits and antibodies.」

「Revenue from this business increased year on year as sales of the core ELISA kits in the reagent business increased, suggesting that research activities at companies and universities are recovering. Meanwhile, although diagnostic raw materials were sold to an overseas company in the pharmaceutical business, revenue declined year on year because there were no sales of veterinary in vitro diagnostic bovine spongiform encephalopathy measurement kits (BSE kits). Expenses increased due to the Company’s active research and development activities. As a result, segment revenue was ¥95.894 million, up 4.9% year on year, and the operating loss was ¥22.357 million, compared with an operating loss of ¥16.584 million in the same period of the previous year.」

「The Group’s strength lies in its advanced antibody production technology, and it mainly provides the following services to public research institutions, universities and pharmaceutical companies.」

「Meanwhile, contract reagent services for certain universities and pharmaceutical companies, as well as sales of veterinary in vitro diagnostic bovine spongiform encephalopathy measurement kits (BSE kits), performed steadily and substantially exceeded the previous year.」

「Revenue from research reagents, including the Company’s core EIA kits and antibodies, declined during the cumulative second quarter under review as customers in Japan and overseas curtailed their research and business activities due to the spread of COVID-19, but increased slightly year on year during the second-quarter accounting period from July to September. Orders for contract reagent services from companies continued relatively steadily, and revenue increased year on year without any impact from COVID-19.」

「Revenue from research reagents, including the Company’s core EIA kits and antibodies, declined by approximately 30% year on year as customers in Japan and overseas curtailed their research and business activities due to the spread of COVID-19.」

「The diagnostic and reagent business has been a core business since the Company’s founding. It manufactures and sells research reagents and in vitro diagnostic products to pharmaceutical companies and university research institutes in the medical field, provides antibody-related contract services, and develops seeds for pharmaceutical raw materials. Customers place their trust in the Company’s technical capabilities.」

「Revenue from research reagents increased year on year because antibody products generated several relatively large transactions. Meanwhile, overseas sales of the core EIA kits declined substantially from the previous year due to factors including the completion of a major project for a CRO, while domestic sales also declined substantially year on year due to factors including stagnation in the reagent market and delays in launching new products. Revenue from contract reagent services declined slightly year on year.」

「In research reagents, sales of antibody products and contract reagent services remained broadly in line with the previous year, but sales of the core EIA kits declined both domestically and overseas compared with the same period of the previous year, due partly to the impact of rush demand at the end of the previous fiscal year.」

「In research reagents, domestic sales of the core EIA measurement kits and antibodies declined, but overseas promotional activities launched in earnest several years ago proved effective, and sales increased as the Company expanded its distributor network into new regions.」

「In research reagents, domestic sales of core antibody-related products declined slightly, but overseas sales increased substantially during the cumulative third quarter under review as the Company focused on building relationships with business partners, actively participating in academic conferences and other events, and signing contracts with new distributors.」

「For the cumulative first quarter under review, the Group’s revenue was ¥171.780 million, up 29.4% year on year, mainly because sales of veterinary in vitro diagnostic bovine spongiform encephalopathy measurement kits (BSE kits), as well as research reagents such as EIA kits and antibodies sold overseas, performed well compared with the same period of the previous year.」

「Revenue from the Company’s core antibody-related reagents increased year on year as both overseas and domestic sales performed steadily.」

「Although revenue from contract services increased substantially year on year as the Company captured user needs through active direct sales, revenue from its in-house-manufactured bovine spongiform encephalopathy measurement kits, veterinary in vitro diagnostic products, declined substantially due to factors including a decrease in the number of tests conducted.」

「In research-related products, overseas sales of the Company’s core EIA measurement kits declined, but revenue from contract services increased substantially year on year as the Company actively sold directly to users and captured their needs.」

「Revenue from contract services also increased substantially year on year as the Company actively sold directly to users and captured their needs.」

「Revenue from contract services increased substantially year on year as the Company actively sold directly to users and captured their needs.」

「The Group’s strength lies in its advanced antibody production technology, and it mainly provides the following services to public research institutions, universities and pharmaceutical companies.」